February 13, 2018 09:31 AM EST
Financing

AI start­up BioX­cel Ther­a­peu­tics shoots for $69M IPO with drugs for Alzheimer's, can­cer

Brittany Meiling

A new ar­ti­fi­cial in­tel­li­gence start­up is toe­ing the IPO wa­ters, an­nounc­ing plans for a $69 mil­lion pub­lic of­fer­ing that may test in­vestors’ ap­petite for risk …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times